Tag Archives: Pandemic

Russia says at least 49,389 people died from COVID-19 in Aug

MOSCOW (Reuters) – At least 49,389 people died in Russia in August due to the coronavirus and related causes, taking the toll to around 418,000 people since the pandemic began, state statistic service Rosstat said on Friday.

Russian authorities blame the spread of the more contagious Delta variant and a low vaccination rate for the third wave of coronavirus infections, which peaked in July.

In July, Russia saw the highest monthly coronavirus death toll of the pandemic as 51,044 people died from COVID-19 or related causes that month, the figure revised recently after the first publication.

The number reported by Rosstat exceeds the official total death toll of 214,485, published by the Russian coronavirus task force earlier on Friday.

Authorities explained the discrepancy between Rosstat and coronavirus task force data by the fact that the latter reports deaths from COVID-19 on a daily basis that do not need additional confirmation from medical examiners, whereas Rosstat publishes full data on a monthly basis.

Some epidemiologists say that measuring excess mortality is the best way to assess the death toll during a pandemic.

Based on the new data, Reuters calculated that the number of excess deaths in Russia between April 2020 and August 2021 had reached 575,000 in comparison with the average mortality rate in 2015-2019.

(Reporting by Gleb Stolyarov; Writing by Andrey Ostroukh; Editing by Alison Williams)

COVID infections dropping throughout the Americas, says health agency

BRASILIA (Reuters) – The number of new COVID-19 infections has been dropping over the past month throughout the Americas, even though only 37% of the people in Latin America and the Caribbean have been fully vaccinated, the Pan American Health Organization (PAHO) said on Wednesday.

However, Alaska has the most serious outbreak in the United States today that is overwhelming emergency rooms, and while South America is continuing to see a drop in infections, Chile has seen a jump in cases in the capital Santiago and port cities Coquimbo and Antofagasta.

PAHO has closed vaccine supply agreements with Sinovac Biotech Inc and AstraZeneca Plc for delivery this year and next and with China’s Sinopharm for 2022, the agency’s director Carissa Etienne told reporters.

(Reporting by Anthony Boadle)

U.S. consumer spending rises, but inflation eroding households purchasing power

By Lucia Mutikani

WASHINGTON(Reuters) – U.S. consumer spending surged in August, but outlays adjusted for inflation were weaker than initially thought in the prior month, reinforcing expectations that economic growth slowed in the third quarter as COVID-19 infections flared up.

The report from the Commerce Department on Friday, which showed inflation remaining hot in August, raised the risk of consumer spending stalling in the third quarter, even if consumption accelerates further in September. Inflation-adjusted, or the so-called real consumer spending is what goes into the calculation of gross domestic product.

“Third quarter consumer spending is on track for only a scant gain,” said Tim Quinlan, a senior economist at Wells Fargo in Charlotte, North Carolina. “If COVID cases keep falling and sentiment turns positive, there is scope for a more solid finish to this tumultuous year.”

Consumer spending, which accounts for more than two-thirds of U.S. economic activity, rebounded 0.8% in August. Data for July was revised down to show spending dipping 0.1% instead of gaining 0.3% as previously reported.

Consumption was boosted by a 1.2% rise in purchases of goods, reflecting increases in spending on food and household supplies as well as recreational items, which offset a drop in motor vehicle outlays. A global shortage of semiconductors is undercutting the production of automobiles, hurting sales.

Goods spending fell 2.1% in July. Spending on services rose 0.6% in August, supported by housing, utilities and health care. Services, which account for the bulk of consumer spending, increased 1.1% in July. Spending is shifting back to services from goods, but the resurgence in coronavirus cases over summer, driven by the Delta variant, crimped demand for air travel and hotel accommodation as well as sales at restaurants and bars.

Economists polled by Reuters had forecast consumer spending increasing 0.6% in August.

Inflation maintained its upward trend in August, though price pressures have probably peaked. The personal consumption expenditures (PCE) price index, excluding the volatile food and energy components, climbed 0.3% after increasing by the same margin in July. In the 12 months through August, the so-called core PCE price index increased 3.6%, matching July’s gain.

The core PCE price index is the Federal Reserve’s preferred inflation measure for its flexible 2% target. The Fed last week upgraded its core PCE inflation projection for this year to 3.7% from 3.0% back in June. The central bank signaled interest rate hikes may follow more quickly than expected.

Fed Chair Jerome Powell, who has maintained that high inflation is transitory, told lawmakers on Thursday that he anticipated some relief in the months ahead.

Still, inflation could remain high for a while. A survey from the Institute for Supply Management on Friday showed manufacturers experienced longer delays getting raw materials delivered to factories and paid higher prices for inputs in September.

Stocks on Wall Street were mostly higher. The dollar fell against a basket of currencies. U.S. Treasury prices were mixed.

SLOWING GROWTH

High inflation is cutting into spending. Real consumer spending rose 0.4% in August. That followed a downwardly revised 0.5% drop in July, which was previously reported as a 0.1% dip. With the August and July data in hand, economists predicted that growth in consumer spending would probably brake to around a 1% annualized rate in the third quarter.

Consumer spending grew at a robust 12.0% annualized rate in the April-June quarter, accounting for much of the economy’s 6.7% growth pace. The level of GDP is now above its peak in the fourth quarter of 2019. In the wake of the consumer spending data, JPMorgan economists lowered their third-quarter GDP estimate to a 4.0% rate from a 5.0% pace.

Overall, the economy remains supported by record corporate profits. Households accumulated at least $2.5 trillion in excess savings during the pandemic. Coronavirus infections are trending down, which is already leading to a rise in demand for travel and other high-contact services. Businesses need to replenish depleted inventories, which will keep factories humming.

A third report on Friday from the University of Michigan showed consumer sentiment ticked higher for the first time in three months in September. But a survey from the Conference Board this week showed consumer confidence dropping to a seven-month low in September.

Though personal income gained only 0.2% in August after rising 1.1% in July as an increase in Child Tax Credit payments from the government was offset by decreases in unemployment insurance checks related to the pandemic, wages are rising as companies compete for scarce workers. Wages rose 0.5% in August, which should help to keep spending supported.

But inflation is eroding consumers’ purchasing power, with income at the disposal of households edging up 0.1% after increasing 1.1% in July. The saving rate fell to a still-high 9.4% from 10.1% in July.

“Households still have plenty left in the tank given rising employment and wages, soaring net worth and massive excess savings,” said Sal Guatieri, a senior economist at BMO Capital Markets in Toronto. “However, rising prices are eating into spending power, compounding the ongoing lack of supply.”

(Reporting by Lucia Mutikani; Editing by Chizu Nomiyama)

Global supply disruptions could still get worse, central bankers warn

By Balazs Koranyi and Francesco Canepa

FRANKFURT (Reuters) – Supply constraints thwarting global economic growth could still get worse, keeping inflation elevated longer, even if the current spike in prices is still likely to remain temporary, the world’s top central bankers warned on Wednesday.

The disruptions to the global economy during the pandemic have upset supply chains across continents, leaving the world short of a plethora of goods and services from car parts and microchips to container vessels that transport goods across the seas.

“It’s … frustrating to see the bottlenecks and supply chain problems not getting better, in fact at the margin apparently getting a little bit worse,” Federal Reserve Chair Jerome Powell told a conference.

“We see that continuing into next year probably and holding inflation up longer than we had thought,” Powell told the European Central Bank’s Forum on Central Banking.

Speaking alongside Powell, ECB chief Christine Lagarde voiced similar concerns, arguing that the end of these bottlenecks, once thought by economists to be just weeks away, is uncertain.

“The supply bottlenecks and the disruption of supply chains, which we have been experiencing for a few months … seem to be continuing and in some sectors accelerating,” Lagarde said. “I’m thinking here about shipping, cargo handling and things like that.”

VERY ATTENTIVE

Global inflation has spiked in recent months on a surge in energy prices, and the production bottlenecks are pushing prices even higher, raising fears that the runup, if it lasts long enough, could seep into expectations and raise the overall profile of inflation.

Indeed, Lagarde said the ECB would be “very attentive” to these second-round effects while Bank of England Governor Andrew Bailey, another speaker at the forum, said he would keep a “very close watch” on inflation expectations.

“If this period of higher inflation, even though it ultimately is very likely to prove temporary, if it lasts long enough, will it start affecting, changing the way people think about inflation? We monitor this very carefully,” Powell added.

The problem is that central banks, the main authority for controlling prices, have no influence over short-term supply disruptions, so they are likely to be bystanders, waiting for economic anomalies to self-correct without lasting damage.

“Monetary policy cannot solve supply side shocks. Monetary policy cannot produce computer chips, it cannot produce wind, it cannot produce truck drivers,” Bailey said.

Still, even as policymakers called for heightened attention to inflation, all maintained their long standing view that the spike in inflation would be temporary and price rises would moderate next year, moving back to or below central bank targets.

Concerns about “sticky” inflation have fueled a debate about the need to unwind crisis-era stimulus measures, and comments from Wednesday’s panel reinforced expectations for the world’s biggest central banks to move on vastly different schedules, staying out of sync for years to come.

The Fed, the BoE and the Bank of Canada have openly discussed policy tightening while central banks in such countries as South Korea, Norway and Hungary have already raised interest rates, beginning a long road to policy normalization.

The ECB and the Bank of Japan are meanwhile likely to be the last movers, exercising extreme caution after undershooting their inflation targets for years.

The ECB even refuses to discuss tapering and already signaled its tolerance for overshooting its inflation target as it would rather move too late than too early.

This sort of patience was only reinforced by Lagarde and Bank of Japan Governor Haruhiko Kuroda, even as both provided a relatively upbeat outlook on growth, arguing that their economies could be back at their pre pandemic levels in the coming months.

(Additional reporting by Leika Kihara, Howard Schneider, Dan Burns, David Milliken and Andy Bruce; Editing by Hugh Lawson)

Protein found on infected cells protects virus from immune system; remdesivir helps prevent hospitalization

By Nancy Lapid

(Reuters) – The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that have yet to be certified by peer review.

Virus-infected cells protected from immune system by protein

A protein called CD47 that helps damaged cells avoid destruction by the immune system may be contributing to severe cases of COVID-19, researchers believe. Drugs in development targeting CD47 may result in improved COVID-19 therapies, they suggested in a report published in Current Issues in Molecular Biology. “We may have identified a major factor associated with severe COVID-19,” coauthor Martin Michaelis of the University of Kent said in a statement. “We can now look forward to further progress in the design of therapeutics.” In lab experiments, the researchers found that CD47 – which in effect tells the immune system, “Do not eat me!” – is present in increased amounts on the surfaces of cells infected with the coronavirus. SARS-CoV-2 infection also increases levels of another protein, SIRPalpha, that partners with CD47 to trick the immune system into ignoring the sick cells. Previous studies have shown that CD47 levels are also elevated in conditions that put people at higher risk for critical illness from COVID-19, such as old age, diabetes, high blood pressure, and clogged blood vessels. In these groups, “high CD47 levels may predispose… to severe COVID-19,” the researchers said. “Further research will be needed to define the roles of CD47 and/or SIRPalpha in COVID-19 in more detail,” they added.

Remdesivir keeps high-risk patients out of the hospital

Gilead Sciences Inc’s intravenous antiviral drug remdesivir helped keep high-risk COVID-19 patients out of the hospital in a randomized trial, the company announced. The 562 patients in the study all had conditions that increased their risk for becoming critically ill. Half received three days of treatment with remdesivir – sold under the brand name Veklury – while the rest received a placebo. Four weeks later, 5.3% of patients in the placebo group had been hospitalized or died, compared to 0.7% of those who received remdesivir. That translated into an 87% lower risk of hospitalization or death. Remdesivir-treated patients also had significantly fewer medical visits, the company said. The drug is currently authorized for emergency use in hospitalized patients. “These latest data show remdesivir’s potential to help high-risk patients recover before they get sicker and stay out of the hospital altogether,” study leader Dr. Robert Gottlieb of Baylor University Medical Center said in a statement. His team plans to formally report the data at an upcoming medical conference.

Pandemic cuts life expectancy by most since WWII

The COVID-19 pandemic has reduced life expectancy in 2020 by the largest amount since World War II, with the life expectancy of American men dropping by more than two years, according to new data. In the 29 countries studied – the United States, Chile, and 27 in Europe – all but two showed reductions in life expectancy. There were greater drops in life expectancy for men than women in most countries. “The large declines in life expectancy observed in the United States can partly be explained by the notable increase in mortality at working ages observed in 2020,” study co-leader Ridhi Kashyap of the University of Oxford said in a statement. “In the United States, increases in mortality in the under 60 age group contributed most significantly to life expectancy declines, whereas across most of Europe increases in mortality above age 60 contributed more significantly.” The largest declines were found in U.S. men, who saw life expectancy drop by 2.2 years relative to 2019, followed by a 1.7-year decline for Lithuanian men. Women in the United States and Spain had drops in life expectancy of 1.5 years or more. Overall, men had more than a year shaved off in 15 countries, compared to women in 11 countries. Females from 15 countries and males from 10 ended up with lower life expectancy at birth in 2020 than in 2015, the research team reported on Sunday in the International Journal of Epidemiology.

(Reporting by Nancy Lapid and Victor Jack; Editing by Bill Berkrot)

South Africa detects new coronavirus variant, still studying its mutations

By Alexander Winning

JOHANNESBURG (Reuters) – South African scientists have detected a new coronavirus variant with multiple mutations but are yet to establish whether it is more contagious or able to overcome the immunity provided by vaccines or prior infection.

The new variant, known as C.1.2, was first detected in May and has now spread to most South African provinces and to seven other countries in Africa, Europe, Asia and Oceania, according to research which is yet to be peer-reviewed.

It contains many mutations associated in other variants with increased transmissibility and reduced sensitivity to neutralizing antibodies, but they occur in a different mix and scientists are not yet sure how they affect the behavior of the virus. Laboratory tests are underway to establish how well the variant is neutralized by antibodies.

South Africa was the first country to detect the Beta variant, one of only four labelled “of concern” by the World Health Organization (WHO).

Beta is believed to spread more easily than the original version of the coronavirus that causes COVID-19, and there is evidence vaccines work less well against it, leading some countries to restrict travel to and from South Africa.

PANDEMIC ‘FAR FROM OVER’

Richard Lessells, an infectious disease specialist and one of the authors of the research on C.1.2, said its emergence tells us “this pandemic is far from over and that this virus is still exploring ways to potentially get better at infecting us.”

He said people should not be overly alarmed at this stage and that variants with more mutations were bound to emerge further into the pandemic.

Genomic sequencing data from South Africa show the C.1.2 variant was still nowhere near displacing the dominant Delta variant in July, the latest month for which a large number of samples was available.

In July C.1.2 accounted for 3% of samples versus 1% in June, whereas Delta accounted for 67% in June and 89% in July.

Delta is the fastest and fittest variant the world has encountered, and it is upending assumptions about COVID-19 even as nations loosen restrictions and reopen their economies.

Lessells said C.1.2 may have more immune evasion properties than Delta, based on its pattern of mutations, and that the findings had been flagged to the WHO.

A spokesman for South Africa’s health department declined to comment on the research.

South Africa’s COVID-19 vaccination campaign got off to a slow start, with only around 14% of its adult population fully vaccinated so far.

(Reporting by Alexander Winning; Editing by Tim Cocks and Gareth Jones)

U.S. coronavirus hospitalizations hit eight-month high over 100,000

By Anurag Maan

(Reuters) -The number of coronavirus patients in U.S. hospitals has breached 100,000, the highest level in eight months, according to the Department of Health and Human Services, as a resurgence of COVID-19 spurred by the highly contagious Delta variant strains the nation’s health care system.

A total of 101,433 COVID patients were hospitalized, according to data published on Friday morning.

U.S. COVID-19 hospitalizations have more than doubled in the past month. Over the past week, more than 500 people with COVID were admitted to hospitals each hour on average, according to data from the Centers for Disease Control and Prevention.

The United States reached its all-time peak for hospitalizations on Jan. 14 when there were over 142,000 coronavirus-infected patients in hospital beds, according to HHS.

As the vaccination campaign expanded in early 2021, hospitalizations fell and hit a 2021 low of 16,000 on in late June.

However, COVID-19 admissions rose suddenly in July as the Delta variant became the dominant strain. The U.S. South is the epicenter of the latest outbreak but hospitalizations are rising nationwide.

Florida has the highest number of COVID-19 hospitalized patients, followed by Texas and California, according to data from the U.S. Department of Health and Human Services. More than 95% of intensive care beds are currently occupied in Alabama, Florida and Georgia.

The Delta variant, which is rapidly spreading among mostly the unvaccinated U.S. population, has also sent a record number of children to hospital. There are currently over 2,000 confirmed and suspected pediatric COVID-19 hospitalizations, according to HHS.

Three states – California, Florida and Texas – amount to about 32% of the total confirmed and suspected pediatric COVID-19 hospitalizations in the United States.

Children currently make up about 2.3% of the nation’s COVID-19 hospitalizations. Kids under 12 are not eligible to receive the vaccine.

The country is hoping for vaccine authorization for younger children by autumn with the Pfizer Inc vaccine.

Dr. Anthony Fauci, the nation’s top infectious disease expert, said this week that the nation could get COVID-19 under control by early next year if vaccinations ramp up.

The United States has given at least one dose of vaccine to about 61% of its population, according to the CDC.

The United States, which leads the world in the most deaths and cases, has reported 38.5 million infections and over 634,000 deaths since the pandemic began last year, according to a Reuters tally.

(Reporting by Anurag Maan in Bengaluru; Editing by Lisa Shumaker and Michael Perry)

Factbox – Latest on the worldwide spread of the coronavirus

(Reuters) – The World Health Organization’s (WHO) pandemic program plans to ship 100 million doses of Sinovac and Sinopharm COVID-19 shots by the end of next month, mostly to Africa and Asia, in its first delivery of Chinese vaccines, a WHO document showed.

EUROPE

* Britain’s Health Department said it has not made any decision on COVID-19 vaccines for 12 to 15-year-olds after the Telegraph reported the National Health Service planned vaccinations from the first week children return to school in September.

* The British public’s view of the government’s management of the coronavirus crisis has turned negative for the first time since February and they are worried about the risk of a new wave of infections, according to a survey.

* Hundreds of Greek frontline health workers protested against a plan to make COVID-19 vaccinations mandatory for the care sector as infection rates remained high.

* Students and teachers who have not been inoculated against COVID-19 or recovered from the disease will have to take weekly tests, as infections in the country rose to their highest since May.

ASIA-PACIFIC

* Vilified by Indian Prime Minister Narendra Modi’s party for its high COVID-19 cases, Kerala’s apparent poor record may actually hold crucial lessons for the country in containing the outbreak as authorities brace for a possible third wave of infections.

* Vietnam will deploy troops to industrial Binh Duong province, a major manufacturing hub in the Southeast Asian country, to help contain an expected 50,000 additional coronavirus infections there over the next two weeks, the government said.

* Thailand is in talks with European countries to purchase millions of doses of COVID-19 vaccines.

AMERICAS

* Illinois will require all eligible students and school employees to be vaccinated and re-instituted an indoor mask mandate under an order announced by Governor J.B. Pritzker.

* Public support for stronger measures to require COVID vaccinations is strong, according to a new Reuters/IPSOS poll, but for Detroit automakers the debate over vaccination policy is far from over.

MIDDLE EAST AND AFRICA

* A third wave of COVID-19 infections in Africa has stabilized and the continent’s slow vaccination drive has picked up pace, the WHO said.

* Qatar is offering COVID-19 vaccines to evacuees from Afghanistan who are temporarily staying in the Gulf Arab state, which has been facilitating global evacuation efforts since the Taliban seized Kabul.

MEDICAL DEVELOPMENTS

* Inovio Pharmaceuticals Inc said it would start a large study for its experimental COVID-19 vaccine in the next few weeks, after the drugmaker received authorization from Brazil’s regulatory agency.

* Pfizer Inc and BioNTech signed on Brazil’s Eurofarma Laboratorios as a manufacturer of their COVID-19 vaccine doses for Latin America.

* Pfizer said a booster dose of its two-shot COVID-19 vaccine spurs a more than threefold increase in antibodies against the coronavirus, as the company seeks U.S. regulatory approval for a third injection.

ECONOMIC IMPACT

* Global equity markets slipped while U.S. Treasury yields rose to two-week highs on Thursday after two hawkish Federal Reserve officials called for the U.S. central bank to start ending its bond-buying program ahead of a key speech by Fed Chair Jerome Powell.

(Compiled by Aditya Soni and Krishna Chandra Eluri; Editing by Subhranshu Sahu and Arun Koyyur)

China criticizes U.S. ‘scapegoating’ as COVID origin report to be released

BEIJING (Reuters) -China criticized on Wednesday the U.S. “politicization” of efforts to trace the origin of the coronavirus, demanding a U.S. military laboratory be investigated, shortly before the release of a U.S. intelligence community report on the virus.

The U.S. report is intended to resolve disputes among intelligence agencies considering different theories about how the coronavirus emerged, including a once-dismissed theory about a Chinese laboratory accident.

“Scapegoating China cannot whitewash the U.S.,” Fu Cong, director-general of the Ministry of Foreign Affairs’ arms control department, told a briefing.

A White House official said on Wednesday that President Joe Biden had been briefed on the classified report. “We look forward to having an unclassified summary of key judgments to share soon,” the official said.

U.S. officials say they did not expect the review to lead to firm conclusions after China stymied earlier international efforts to gather key information on the ground.

China has said a laboratory leak was highly unlikely, and it has ridiculed a theory that coronavirus escaped from a lab in Wuhan, the city where COVID-19 infections emerged in late 2019, setting off the pandemic.

China has instead suggested that the virus slipped out of a lab at the Army’s Fort Detrick base in Maryland in 2019.

“It is only fair that if the U.S. insists that this is a valid hypothesis, they should do their turn and invite the investigation into their labs,” said Fu.

On Tuesday, China’s envoy to the United Nations asked the head of the World Health Organization for an investigation into U.S. labs.

A joint WHO-Chinese team visited the Wuhan Institute of Virology but the United States said it had concerns about the access granted to the investigation.

When asked if China would stop talking about the Fort Detrick laboratory if the U.S. report concluded the virus did not leak from a Chinese lab, Fu said: “That is a hypothetical question, you need to ask the U.S.”

Fu said China was not engaged in a disinformation campaign.

(Reporting by Gabriel Crossley; additional reporting by Steve Holland in Washington; editing by Jonathan Oatis)

U.S. extends travel curbs at Canada and Mexico land borders

By David Shepardson

WASHINGTON (Reuters) -The United States on Friday extended the closure of its land borders with Canada and Mexico to non-essential travel such as tourism through Sept. 21 despite Ottawa’s decision to open its border to vaccinated Americans.

The latest 30-day extension by the Department of Homeland Security (DHS), came after Canada said in July it would start allowing in fully vaccinated U.S. visitors starting Aug. 9 for non-essential travel after the COVID-19 pandemic prompted a lengthy ban that many businesses have called crippling.

“In coordination with public health and medical experts, DHS continues working closely with its partners across the United States and internationally to determine how to safely and sustainably resume normal travel,” DHS said on Twitter.

The United States has continued to extend the extraordinary restrictions on Canada and Mexico on a monthly basis since March 2020, when they were imposed to address the spread of COVID-19. Reuters reported this week the extension was expected.

The latest restrictions extend the prohibitions beyond the end of the busy U.S. summer tourism season. Airline officials say it will be at least weeks and potentially months before any U.S. travel restrictions are lifted, citing the rising number of COVID-19 cases.

The U.S. land border restrictions do not bar U.S. citizens and lawful permanent residents from returning to the United States.

Separate from the Canada and Mexico land border restrictions, the United States bars most non-U.S. citizens who within the last 14 days have been in the United Kingdom, the 26 Schengen countries in Europe without border controls, Ireland, China, India, South Africa, Iran and Brazil.

The White House confirmed on Aug. 5 it may require visitors from abroad to be vaccinated as part of its plans to eventually reopen international travel but it had yet to decide and would not immediately lift restrictions.

The White House in June launched interagency working groups with the European Union, Britain, Canada and Mexico to look at how eventually to lift travel and border restrictions.

(Reporting by David Shepardson; Editing by Gareth Jones and Timothy Heritage)